Zymogenetics, Inc.

Bristol-myers Squibb Compnay

Chung Chan

Kevin M Klucher

Paul O Sheppard

Thomas R Bukowski

Dennis L Dong

Lowell J Brady

Hong Yan Liu

Wayne R Kindsvogel

Hong Liu

Pallavur V Sivakumar

Sean E Doyle

Tracey A Pownder

Susan D Holderman

Bruce L Zamost

Jeffrey D Meyer

Karen S De Jongh

Douglas C Covert

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Mutants of IL-29

Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.

Use of IL-28 and IL-29 to treat cancer and autoimmune disorders

Method of using IL-29 cystehne mutant to treat hepatitis C and hepatitis B

Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B

Polynucleotide encoding an IL-28A polypeptide

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.

Isolated nucleic acid sequence comprising SEQ ID NO: 14 and methods of using said nucleic acid sequence

Polynucleotide encoding an IL-28A polypepide

Polynucleotide encoding an IL-28B polypeptide

Growing community of inventors

Issaquah, WA, United States of America

Chung Chan